Published on 22/10/202522/10/2025 by Environmental Scientists 63 / 100 Powered by Rank Math SEO SEO Score Dr. Helene Laude | Malnutrition | Best Researcher Award Institute Pasteur | France Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus Featured Publications Karagas, M. R., Kaldor, J., Michaelis, M., Muchengeti, M. M., Alfaiate, D., Argirion, I., Chen, X., Cunha, C., Hantz, S., Koljonen, V., Laude, H. C., Lui, W. O., Nevels, M. M., O’Brien, T. R., Scheurer, M. E., Touze, A., Wiemels, J. L., Benbrahim-Tallaa, L., de Conti, A., Facchin, C., Madia, F., Pasqual, E., Wedekind, R., Aguilera-Buenosvinos, I., Clifford, G., Deng, X., Dongoran, R. A., Ezzemni, S., Huang, Y., Suonio, E., Zhai, Y., Mattock, H., Schubauer-Berigan, M. K., & Kunzmann, A. T. (2025). Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. Lancet Oncology, S1470-2045(25)00403-6. Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., Samson, M., Sangari, L., Ungeheuer, M. N., Vacant, S., Zayoud, A., Donnadieu, F., Pelleau, S., Galmiche, S., Fontanet, A., & White, M. (2025). Correlates of protection against symptomatic COVID-19: The CORSER 5 case-control study. Open Forum Infectious Diseases, 12(1). Combes, J. D., Didelot, J. M., Radenne, S., Zaegel-Faucher, O., Lesage, A. C., Siproudhis, L., Piroth, L., Marchand, L., Heard, I., Hoyeau, N., Henno, S., Darragh, T. M., Alberts, C. J., Clifford, G. M., & Etienney, I.; ANRS-EP57-APACHES Study group. (2024). Cumulative detection of anal high-grade squamous intraepithelial lesions over 2-year follow-up in men who have sex with men living with human immunodeficiency virus in France. Journal of Infectious Diseases, 230(1). Martinez, F. J., Guillotte-Blisnick, M., Huon, C., England, P., Popovici, J., Laude, H., Arowas, L., Ungeheuer, M. N., Reimer, J. M., Carter, D., Reed, S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2023). Immunogenicity of a Plasmodium vivax vaccine based on the Duffy binding protein formulated using adjuvants compatible for use in humans. Scientific Reports, 13(1), 13904. Cuche, C., Mastrogiovanni, M., Juzans, M., Laude, H., Ungeheuer, M. N., Krentzel, D., Gariboldi, M. I., Scott-Algara, D., Madec, M., Goyard, S., Floch, C., Chauveau-Le Friec, G., Lafaye, P., Renaudat, C., Le Bidan, M., Micallef, C., Schmutz, S., Mella, S., Novault, S., Hasan, M., Duffy, D., Di Bartolo, V., & Alcover, A. (2023). T cell migration and effector function differences in familial adenomatous polyposis patients with APC gene mutations. Frontiers in Immunology, 14, 1163466. Helene Laude | Malnutrition | Best Researcher Award
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Dr. Helene Laude, MD, PhD, is a distinguished French physician-scientist recognized for her expertise in virology, immunology, and infectious diseases. Currently affiliated with the Institute Pasteur, she has made significant contributions to understanding viral pathogenesis, host immunity, and infection-related carcinogenesis. Her research has advanced knowledge on viruses such as SARS-CoV-2, Monkeypox, Zika, and various oncogenic viruses including Merkel polyomavirus and cytomegalovirus. Dr. Helene Laude has served as principal investigator for major clinical and immunological studies, focusing on mucosal immunity, biomarker discovery, and population-based cohort investigations. With 998 citations by 853 documents, 32 publications, and an h-index of 15, her scholarly impact underscores her leadership in translational virology and public health research. Her publications in The Lancet Oncology, Scientific Reports, Frontiers in Immunology, and Cell Host & Microbe highlight her dedication to advancing biomedical science. A respected expert and reviewer for leading organizations such as ANRS, INCa, and IARC, she contributes to global evaluations on viral carcinogenicity and diagnostic innovation. Beyond research, Dr. Helene Laude is actively involved in academic teaching at renowned institutions including the Institute Pasteur, Sorbonne University, and Paris Descartes University, mentoring future scientists and medical professionals in vaccinology, virology, and cancer immunology. Her achievements exemplify excellence in clinical investigation and molecular medicine, bridging laboratory discoveries with human health applications to enhance global infectious disease preparedness and cancer prevention. Profiles: Scopus
Featured Publications Karagas, M. R., Kaldor, J., Michaelis, M., Muchengeti, M. M., Alfaiate, D., Argirion, I., Chen, X., Cunha, C., Hantz, S., Koljonen, V., Laude, H. C., Lui, W. O., Nevels, M. M., O’Brien, T. R., Scheurer, M. E., Touze, A., Wiemels, J. L., Benbrahim-Tallaa, L., de Conti, A., Facchin, C., Madia, F., Pasqual, E., Wedekind, R., Aguilera-Buenosvinos, I., Clifford, G., Deng, X., Dongoran, R. A., Ezzemni, S., Huang, Y., Suonio, E., Zhai, Y., Mattock, H., Schubauer-Berigan, M. K., & Kunzmann, A. T. (2025). Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. Lancet Oncology, S1470-2045(25)00403-6. Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., Samson, M., Sangari, L., Ungeheuer, M. N., Vacant, S., Zayoud, A., Donnadieu, F., Pelleau, S., Galmiche, S., Fontanet, A., & White, M. (2025). Correlates of protection against symptomatic COVID-19: The CORSER 5 case-control study. Open Forum Infectious Diseases, 12(1). Combes, J. D., Didelot, J. M., Radenne, S., Zaegel-Faucher, O., Lesage, A. C., Siproudhis, L., Piroth, L., Marchand, L., Heard, I., Hoyeau, N., Henno, S., Darragh, T. M., Alberts, C. J., Clifford, G. M., & Etienney, I.; ANRS-EP57-APACHES Study group. (2024). Cumulative detection of anal high-grade squamous intraepithelial lesions over 2-year follow-up in men who have sex with men living with human immunodeficiency virus in France. Journal of Infectious Diseases, 230(1). Martinez, F. J., Guillotte-Blisnick, M., Huon, C., England, P., Popovici, J., Laude, H., Arowas, L., Ungeheuer, M. N., Reimer, J. M., Carter, D., Reed, S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2023). Immunogenicity of a Plasmodium vivax vaccine based on the Duffy binding protein formulated using adjuvants compatible for use in humans. Scientific Reports, 13(1), 13904. Cuche, C., Mastrogiovanni, M., Juzans, M., Laude, H., Ungeheuer, M. N., Krentzel, D., Gariboldi, M. I., Scott-Algara, D., Madec, M., Goyard, S., Floch, C., Chauveau-Le Friec, G., Lafaye, P., Renaudat, C., Le Bidan, M., Micallef, C., Schmutz, S., Mella, S., Novault, S., Hasan, M., Duffy, D., Di Bartolo, V., & Alcover, A. (2023). T cell migration and effector function differences in familial adenomatous polyposis patients with APC gene mutations. Frontiers in Immunology, 14, 1163466.
Featured Publications Karagas, M. R., Kaldor, J., Michaelis, M., Muchengeti, M. M., Alfaiate, D., Argirion, I., Chen, X., Cunha, C., Hantz, S., Koljonen, V., Laude, H. C., Lui, W. O., Nevels, M. M., O’Brien, T. R., Scheurer, M. E., Touze, A., Wiemels, J. L., Benbrahim-Tallaa, L., de Conti, A., Facchin, C., Madia, F., Pasqual, E., Wedekind, R., Aguilera-Buenosvinos, I., Clifford, G., Deng, X., Dongoran, R. A., Ezzemni, S., Huang, Y., Suonio, E., Zhai, Y., Mattock, H., Schubauer-Berigan, M. K., & Kunzmann, A. T. (2025). Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. Lancet Oncology, S1470-2045(25)00403-6. Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., Samson, M., Sangari, L., Ungeheuer, M. N., Vacant, S., Zayoud, A., Donnadieu, F., Pelleau, S., Galmiche, S., Fontanet, A., & White, M. (2025). Correlates of protection against symptomatic COVID-19: The CORSER 5 case-control study. Open Forum Infectious Diseases, 12(1). Combes, J. D., Didelot, J. M., Radenne, S., Zaegel-Faucher, O., Lesage, A. C., Siproudhis, L., Piroth, L., Marchand, L., Heard, I., Hoyeau, N., Henno, S., Darragh, T. M., Alberts, C. J., Clifford, G. M., & Etienney, I.; ANRS-EP57-APACHES Study group. (2024). Cumulative detection of anal high-grade squamous intraepithelial lesions over 2-year follow-up in men who have sex with men living with human immunodeficiency virus in France. Journal of Infectious Diseases, 230(1). Martinez, F. J., Guillotte-Blisnick, M., Huon, C., England, P., Popovici, J., Laude, H., Arowas, L., Ungeheuer, M. N., Reimer, J. M., Carter, D., Reed, S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2023). Immunogenicity of a Plasmodium vivax vaccine based on the Duffy binding protein formulated using adjuvants compatible for use in humans. Scientific Reports, 13(1), 13904. Cuche, C., Mastrogiovanni, M., Juzans, M., Laude, H., Ungeheuer, M. N., Krentzel, D., Gariboldi, M. I., Scott-Algara, D., Madec, M., Goyard, S., Floch, C., Chauveau-Le Friec, G., Lafaye, P., Renaudat, C., Le Bidan, M., Micallef, C., Schmutz, S., Mella, S., Novault, S., Hasan, M., Duffy, D., Di Bartolo, V., & Alcover, A. (2023). T cell migration and effector function differences in familial adenomatous polyposis patients with APC gene mutations. Frontiers in Immunology, 14, 1163466.
Featured Publications Karagas, M. R., Kaldor, J., Michaelis, M., Muchengeti, M. M., Alfaiate, D., Argirion, I., Chen, X., Cunha, C., Hantz, S., Koljonen, V., Laude, H. C., Lui, W. O., Nevels, M. M., O’Brien, T. R., Scheurer, M. E., Touze, A., Wiemels, J. L., Benbrahim-Tallaa, L., de Conti, A., Facchin, C., Madia, F., Pasqual, E., Wedekind, R., Aguilera-Buenosvinos, I., Clifford, G., Deng, X., Dongoran, R. A., Ezzemni, S., Huang, Y., Suonio, E., Zhai, Y., Mattock, H., Schubauer-Berigan, M. K., & Kunzmann, A. T. (2025). Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. Lancet Oncology, S1470-2045(25)00403-6. Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., Samson, M., Sangari, L., Ungeheuer, M. N., Vacant, S., Zayoud, A., Donnadieu, F., Pelleau, S., Galmiche, S., Fontanet, A., & White, M. (2025). Correlates of protection against symptomatic COVID-19: The CORSER 5 case-control study. Open Forum Infectious Diseases, 12(1). Combes, J. D., Didelot, J. M., Radenne, S., Zaegel-Faucher, O., Lesage, A. C., Siproudhis, L., Piroth, L., Marchand, L., Heard, I., Hoyeau, N., Henno, S., Darragh, T. M., Alberts, C. J., Clifford, G. M., & Etienney, I.; ANRS-EP57-APACHES Study group. (2024). Cumulative detection of anal high-grade squamous intraepithelial lesions over 2-year follow-up in men who have sex with men living with human immunodeficiency virus in France. Journal of Infectious Diseases, 230(1). Martinez, F. J., Guillotte-Blisnick, M., Huon, C., England, P., Popovici, J., Laude, H., Arowas, L., Ungeheuer, M. N., Reimer, J. M., Carter, D., Reed, S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2023). Immunogenicity of a Plasmodium vivax vaccine based on the Duffy binding protein formulated using adjuvants compatible for use in humans. Scientific Reports, 13(1), 13904. Cuche, C., Mastrogiovanni, M., Juzans, M., Laude, H., Ungeheuer, M. N., Krentzel, D., Gariboldi, M. I., Scott-Algara, D., Madec, M., Goyard, S., Floch, C., Chauveau-Le Friec, G., Lafaye, P., Renaudat, C., Le Bidan, M., Micallef, C., Schmutz, S., Mella, S., Novault, S., Hasan, M., Duffy, D., Di Bartolo, V., & Alcover, A. (2023). T cell migration and effector function differences in familial adenomatous polyposis patients with APC gene mutations. Frontiers in Immunology, 14, 1163466.
Featured Publications Karagas, M. R., Kaldor, J., Michaelis, M., Muchengeti, M. M., Alfaiate, D., Argirion, I., Chen, X., Cunha, C., Hantz, S., Koljonen, V., Laude, H. C., Lui, W. O., Nevels, M. M., O’Brien, T. R., Scheurer, M. E., Touze, A., Wiemels, J. L., Benbrahim-Tallaa, L., de Conti, A., Facchin, C., Madia, F., Pasqual, E., Wedekind, R., Aguilera-Buenosvinos, I., Clifford, G., Deng, X., Dongoran, R. A., Ezzemni, S., Huang, Y., Suonio, E., Zhai, Y., Mattock, H., Schubauer-Berigan, M. K., & Kunzmann, A. T. (2025). Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. Lancet Oncology, S1470-2045(25)00403-6. Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., Samson, M., Sangari, L., Ungeheuer, M. N., Vacant, S., Zayoud, A., Donnadieu, F., Pelleau, S., Galmiche, S., Fontanet, A., & White, M. (2025). Correlates of protection against symptomatic COVID-19: The CORSER 5 case-control study. Open Forum Infectious Diseases, 12(1). Combes, J. D., Didelot, J. M., Radenne, S., Zaegel-Faucher, O., Lesage, A. C., Siproudhis, L., Piroth, L., Marchand, L., Heard, I., Hoyeau, N., Henno, S., Darragh, T. M., Alberts, C. J., Clifford, G. M., & Etienney, I.; ANRS-EP57-APACHES Study group. (2024). Cumulative detection of anal high-grade squamous intraepithelial lesions over 2-year follow-up in men who have sex with men living with human immunodeficiency virus in France. Journal of Infectious Diseases, 230(1). Martinez, F. J., Guillotte-Blisnick, M., Huon, C., England, P., Popovici, J., Laude, H., Arowas, L., Ungeheuer, M. N., Reimer, J. M., Carter, D., Reed, S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2023). Immunogenicity of a Plasmodium vivax vaccine based on the Duffy binding protein formulated using adjuvants compatible for use in humans. Scientific Reports, 13(1), 13904. Cuche, C., Mastrogiovanni, M., Juzans, M., Laude, H., Ungeheuer, M. N., Krentzel, D., Gariboldi, M. I., Scott-Algara, D., Madec, M., Goyard, S., Floch, C., Chauveau-Le Friec, G., Lafaye, P., Renaudat, C., Le Bidan, M., Micallef, C., Schmutz, S., Mella, S., Novault, S., Hasan, M., Duffy, D., Di Bartolo, V., & Alcover, A. (2023). T cell migration and effector function differences in familial adenomatous polyposis patients with APC gene mutations. Frontiers in Immunology, 14, 1163466.
Featured Publications Karagas, M. R., Kaldor, J., Michaelis, M., Muchengeti, M. M., Alfaiate, D., Argirion, I., Chen, X., Cunha, C., Hantz, S., Koljonen, V., Laude, H. C., Lui, W. O., Nevels, M. M., O’Brien, T. R., Scheurer, M. E., Touze, A., Wiemels, J. L., Benbrahim-Tallaa, L., de Conti, A., Facchin, C., Madia, F., Pasqual, E., Wedekind, R., Aguilera-Buenosvinos, I., Clifford, G., Deng, X., Dongoran, R. A., Ezzemni, S., Huang, Y., Suonio, E., Zhai, Y., Mattock, H., Schubauer-Berigan, M. K., & Kunzmann, A. T. (2025). Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. Lancet Oncology, S1470-2045(25)00403-6. Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., Samson, M., Sangari, L., Ungeheuer, M. N., Vacant, S., Zayoud, A., Donnadieu, F., Pelleau, S., Galmiche, S., Fontanet, A., & White, M. (2025). Correlates of protection against symptomatic COVID-19: The CORSER 5 case-control study. Open Forum Infectious Diseases, 12(1). Combes, J. D., Didelot, J. M., Radenne, S., Zaegel-Faucher, O., Lesage, A. C., Siproudhis, L., Piroth, L., Marchand, L., Heard, I., Hoyeau, N., Henno, S., Darragh, T. M., Alberts, C. J., Clifford, G. M., & Etienney, I.; ANRS-EP57-APACHES Study group. (2024). Cumulative detection of anal high-grade squamous intraepithelial lesions over 2-year follow-up in men who have sex with men living with human immunodeficiency virus in France. Journal of Infectious Diseases, 230(1). Martinez, F. J., Guillotte-Blisnick, M., Huon, C., England, P., Popovici, J., Laude, H., Arowas, L., Ungeheuer, M. N., Reimer, J. M., Carter, D., Reed, S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2023). Immunogenicity of a Plasmodium vivax vaccine based on the Duffy binding protein formulated using adjuvants compatible for use in humans. Scientific Reports, 13(1), 13904. Cuche, C., Mastrogiovanni, M., Juzans, M., Laude, H., Ungeheuer, M. N., Krentzel, D., Gariboldi, M. I., Scott-Algara, D., Madec, M., Goyard, S., Floch, C., Chauveau-Le Friec, G., Lafaye, P., Renaudat, C., Le Bidan, M., Micallef, C., Schmutz, S., Mella, S., Novault, S., Hasan, M., Duffy, D., Di Bartolo, V., & Alcover, A. (2023). T cell migration and effector function differences in familial adenomatous polyposis patients with APC gene mutations. Frontiers in Immunology, 14, 1163466.
Featured Publications Karagas, M. R., Kaldor, J., Michaelis, M., Muchengeti, M. M., Alfaiate, D., Argirion, I., Chen, X., Cunha, C., Hantz, S., Koljonen, V., Laude, H. C., Lui, W. O., Nevels, M. M., O’Brien, T. R., Scheurer, M. E., Touze, A., Wiemels, J. L., Benbrahim-Tallaa, L., de Conti, A., Facchin, C., Madia, F., Pasqual, E., Wedekind, R., Aguilera-Buenosvinos, I., Clifford, G., Deng, X., Dongoran, R. A., Ezzemni, S., Huang, Y., Suonio, E., Zhai, Y., Mattock, H., Schubauer-Berigan, M. K., & Kunzmann, A. T. (2025). Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. Lancet Oncology, S1470-2045(25)00403-6. Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., Samson, M., Sangari, L., Ungeheuer, M. N., Vacant, S., Zayoud, A., Donnadieu, F., Pelleau, S., Galmiche, S., Fontanet, A., & White, M. (2025). Correlates of protection against symptomatic COVID-19: The CORSER 5 case-control study. Open Forum Infectious Diseases, 12(1). Combes, J. D., Didelot, J. M., Radenne, S., Zaegel-Faucher, O., Lesage, A. C., Siproudhis, L., Piroth, L., Marchand, L., Heard, I., Hoyeau, N., Henno, S., Darragh, T. M., Alberts, C. J., Clifford, G. M., & Etienney, I.; ANRS-EP57-APACHES Study group. (2024). Cumulative detection of anal high-grade squamous intraepithelial lesions over 2-year follow-up in men who have sex with men living with human immunodeficiency virus in France. Journal of Infectious Diseases, 230(1). Martinez, F. J., Guillotte-Blisnick, M., Huon, C., England, P., Popovici, J., Laude, H., Arowas, L., Ungeheuer, M. N., Reimer, J. M., Carter, D., Reed, S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2023). Immunogenicity of a Plasmodium vivax vaccine based on the Duffy binding protein formulated using adjuvants compatible for use in humans. Scientific Reports, 13(1), 13904. Cuche, C., Mastrogiovanni, M., Juzans, M., Laude, H., Ungeheuer, M. N., Krentzel, D., Gariboldi, M. I., Scott-Algara, D., Madec, M., Goyard, S., Floch, C., Chauveau-Le Friec, G., Lafaye, P., Renaudat, C., Le Bidan, M., Micallef, C., Schmutz, S., Mella, S., Novault, S., Hasan, M., Duffy, D., Di Bartolo, V., & Alcover, A. (2023). T cell migration and effector function differences in familial adenomatous polyposis patients with APC gene mutations. Frontiers in Immunology, 14, 1163466.
Featured Publications Karagas, M. R., Kaldor, J., Michaelis, M., Muchengeti, M. M., Alfaiate, D., Argirion, I., Chen, X., Cunha, C., Hantz, S., Koljonen, V., Laude, H. C., Lui, W. O., Nevels, M. M., O’Brien, T. R., Scheurer, M. E., Touze, A., Wiemels, J. L., Benbrahim-Tallaa, L., de Conti, A., Facchin, C., Madia, F., Pasqual, E., Wedekind, R., Aguilera-Buenosvinos, I., Clifford, G., Deng, X., Dongoran, R. A., Ezzemni, S., Huang, Y., Suonio, E., Zhai, Y., Mattock, H., Schubauer-Berigan, M. K., & Kunzmann, A. T. (2025). Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. Lancet Oncology, S1470-2045(25)00403-6. Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., Samson, M., Sangari, L., Ungeheuer, M. N., Vacant, S., Zayoud, A., Donnadieu, F., Pelleau, S., Galmiche, S., Fontanet, A., & White, M. (2025). Correlates of protection against symptomatic COVID-19: The CORSER 5 case-control study. Open Forum Infectious Diseases, 12(1). Combes, J. D., Didelot, J. M., Radenne, S., Zaegel-Faucher, O., Lesage, A. C., Siproudhis, L., Piroth, L., Marchand, L., Heard, I., Hoyeau, N., Henno, S., Darragh, T. M., Alberts, C. J., Clifford, G. M., & Etienney, I.; ANRS-EP57-APACHES Study group. (2024). Cumulative detection of anal high-grade squamous intraepithelial lesions over 2-year follow-up in men who have sex with men living with human immunodeficiency virus in France. Journal of Infectious Diseases, 230(1). Martinez, F. J., Guillotte-Blisnick, M., Huon, C., England, P., Popovici, J., Laude, H., Arowas, L., Ungeheuer, M. N., Reimer, J. M., Carter, D., Reed, S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2023). Immunogenicity of a Plasmodium vivax vaccine based on the Duffy binding protein formulated using adjuvants compatible for use in humans. Scientific Reports, 13(1), 13904. Cuche, C., Mastrogiovanni, M., Juzans, M., Laude, H., Ungeheuer, M. N., Krentzel, D., Gariboldi, M. I., Scott-Algara, D., Madec, M., Goyard, S., Floch, C., Chauveau-Le Friec, G., Lafaye, P., Renaudat, C., Le Bidan, M., Micallef, C., Schmutz, S., Mella, S., Novault, S., Hasan, M., Duffy, D., Di Bartolo, V., & Alcover, A. (2023). T cell migration and effector function differences in familial adenomatous polyposis patients with APC gene mutations. Frontiers in Immunology, 14, 1163466.
Featured Publications Karagas, M. R., Kaldor, J., Michaelis, M., Muchengeti, M. M., Alfaiate, D., Argirion, I., Chen, X., Cunha, C., Hantz, S., Koljonen, V., Laude, H. C., Lui, W. O., Nevels, M. M., O’Brien, T. R., Scheurer, M. E., Touze, A., Wiemels, J. L., Benbrahim-Tallaa, L., de Conti, A., Facchin, C., Madia, F., Pasqual, E., Wedekind, R., Aguilera-Buenosvinos, I., Clifford, G., Deng, X., Dongoran, R. A., Ezzemni, S., Huang, Y., Suonio, E., Zhai, Y., Mattock, H., Schubauer-Berigan, M. K., & Kunzmann, A. T. (2025). Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. Lancet Oncology, S1470-2045(25)00403-6. Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., Samson, M., Sangari, L., Ungeheuer, M. N., Vacant, S., Zayoud, A., Donnadieu, F., Pelleau, S., Galmiche, S., Fontanet, A., & White, M. (2025). Correlates of protection against symptomatic COVID-19: The CORSER 5 case-control study. Open Forum Infectious Diseases, 12(1). Combes, J. D., Didelot, J. M., Radenne, S., Zaegel-Faucher, O., Lesage, A. C., Siproudhis, L., Piroth, L., Marchand, L., Heard, I., Hoyeau, N., Henno, S., Darragh, T. M., Alberts, C. J., Clifford, G. M., & Etienney, I.; ANRS-EP57-APACHES Study group. (2024). Cumulative detection of anal high-grade squamous intraepithelial lesions over 2-year follow-up in men who have sex with men living with human immunodeficiency virus in France. Journal of Infectious Diseases, 230(1). Martinez, F. J., Guillotte-Blisnick, M., Huon, C., England, P., Popovici, J., Laude, H., Arowas, L., Ungeheuer, M. N., Reimer, J. M., Carter, D., Reed, S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2023). Immunogenicity of a Plasmodium vivax vaccine based on the Duffy binding protein formulated using adjuvants compatible for use in humans. Scientific Reports, 13(1), 13904. Cuche, C., Mastrogiovanni, M., Juzans, M., Laude, H., Ungeheuer, M. N., Krentzel, D., Gariboldi, M. I., Scott-Algara, D., Madec, M., Goyard, S., Floch, C., Chauveau-Le Friec, G., Lafaye, P., Renaudat, C., Le Bidan, M., Micallef, C., Schmutz, S., Mella, S., Novault, S., Hasan, M., Duffy, D., Di Bartolo, V., & Alcover, A. (2023). T cell migration and effector function differences in familial adenomatous polyposis patients with APC gene mutations. Frontiers in Immunology, 14, 1163466.
Featured Publications Karagas, M. R., Kaldor, J., Michaelis, M., Muchengeti, M. M., Alfaiate, D., Argirion, I., Chen, X., Cunha, C., Hantz, S., Koljonen, V., Laude, H. C., Lui, W. O., Nevels, M. M., O’Brien, T. R., Scheurer, M. E., Touze, A., Wiemels, J. L., Benbrahim-Tallaa, L., de Conti, A., Facchin, C., Madia, F., Pasqual, E., Wedekind, R., Aguilera-Buenosvinos, I., Clifford, G., Deng, X., Dongoran, R. A., Ezzemni, S., Huang, Y., Suonio, E., Zhai, Y., Mattock, H., Schubauer-Berigan, M. K., & Kunzmann, A. T. (2025). Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. Lancet Oncology, S1470-2045(25)00403-6. Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., Samson, M., Sangari, L., Ungeheuer, M. N., Vacant, S., Zayoud, A., Donnadieu, F., Pelleau, S., Galmiche, S., Fontanet, A., & White, M. (2025). Correlates of protection against symptomatic COVID-19: The CORSER 5 case-control study. Open Forum Infectious Diseases, 12(1). Combes, J. D., Didelot, J. M., Radenne, S., Zaegel-Faucher, O., Lesage, A. C., Siproudhis, L., Piroth, L., Marchand, L., Heard, I., Hoyeau, N., Henno, S., Darragh, T. M., Alberts, C. J., Clifford, G. M., & Etienney, I.; ANRS-EP57-APACHES Study group. (2024). Cumulative detection of anal high-grade squamous intraepithelial lesions over 2-year follow-up in men who have sex with men living with human immunodeficiency virus in France. Journal of Infectious Diseases, 230(1). Martinez, F. J., Guillotte-Blisnick, M., Huon, C., England, P., Popovici, J., Laude, H., Arowas, L., Ungeheuer, M. N., Reimer, J. M., Carter, D., Reed, S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2023). Immunogenicity of a Plasmodium vivax vaccine based on the Duffy binding protein formulated using adjuvants compatible for use in humans. Scientific Reports, 13(1), 13904. Cuche, C., Mastrogiovanni, M., Juzans, M., Laude, H., Ungeheuer, M. N., Krentzel, D., Gariboldi, M. I., Scott-Algara, D., Madec, M., Goyard, S., Floch, C., Chauveau-Le Friec, G., Lafaye, P., Renaudat, C., Le Bidan, M., Micallef, C., Schmutz, S., Mella, S., Novault, S., Hasan, M., Duffy, D., Di Bartolo, V., & Alcover, A. (2023). T cell migration and effector function differences in familial adenomatous polyposis patients with APC gene mutations. Frontiers in Immunology, 14, 1163466.
Featured Publications Karagas, M. R., Kaldor, J., Michaelis, M., Muchengeti, M. M., Alfaiate, D., Argirion, I., Chen, X., Cunha, C., Hantz, S., Koljonen, V., Laude, H. C., Lui, W. O., Nevels, M. M., O’Brien, T. R., Scheurer, M. E., Touze, A., Wiemels, J. L., Benbrahim-Tallaa, L., de Conti, A., Facchin, C., Madia, F., Pasqual, E., Wedekind, R., Aguilera-Buenosvinos, I., Clifford, G., Deng, X., Dongoran, R. A., Ezzemni, S., Huang, Y., Suonio, E., Zhai, Y., Mattock, H., Schubauer-Berigan, M. K., & Kunzmann, A. T. (2025). Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. Lancet Oncology, S1470-2045(25)00403-6. Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., Samson, M., Sangari, L., Ungeheuer, M. N., Vacant, S., Zayoud, A., Donnadieu, F., Pelleau, S., Galmiche, S., Fontanet, A., & White, M. (2025). Correlates of protection against symptomatic COVID-19: The CORSER 5 case-control study. Open Forum Infectious Diseases, 12(1). Combes, J. D., Didelot, J. M., Radenne, S., Zaegel-Faucher, O., Lesage, A. C., Siproudhis, L., Piroth, L., Marchand, L., Heard, I., Hoyeau, N., Henno, S., Darragh, T. M., Alberts, C. J., Clifford, G. M., & Etienney, I.; ANRS-EP57-APACHES Study group. (2024). Cumulative detection of anal high-grade squamous intraepithelial lesions over 2-year follow-up in men who have sex with men living with human immunodeficiency virus in France. Journal of Infectious Diseases, 230(1). Martinez, F. J., Guillotte-Blisnick, M., Huon, C., England, P., Popovici, J., Laude, H., Arowas, L., Ungeheuer, M. N., Reimer, J. M., Carter, D., Reed, S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2023). Immunogenicity of a Plasmodium vivax vaccine based on the Duffy binding protein formulated using adjuvants compatible for use in humans. Scientific Reports, 13(1), 13904. Cuche, C., Mastrogiovanni, M., Juzans, M., Laude, H., Ungeheuer, M. N., Krentzel, D., Gariboldi, M. I., Scott-Algara, D., Madec, M., Goyard, S., Floch, C., Chauveau-Le Friec, G., Lafaye, P., Renaudat, C., Le Bidan, M., Micallef, C., Schmutz, S., Mella, S., Novault, S., Hasan, M., Duffy, D., Di Bartolo, V., & Alcover, A. (2023). T cell migration and effector function differences in familial adenomatous polyposis patients with APC gene mutations. Frontiers in Immunology, 14, 1163466.
Featured Publications Karagas, M. R., Kaldor, J., Michaelis, M., Muchengeti, M. M., Alfaiate, D., Argirion, I., Chen, X., Cunha, C., Hantz, S., Koljonen, V., Laude, H. C., Lui, W. O., Nevels, M. M., O’Brien, T. R., Scheurer, M. E., Touze, A., Wiemels, J. L., Benbrahim-Tallaa, L., de Conti, A., Facchin, C., Madia, F., Pasqual, E., Wedekind, R., Aguilera-Buenosvinos, I., Clifford, G., Deng, X., Dongoran, R. A., Ezzemni, S., Huang, Y., Suonio, E., Zhai, Y., Mattock, H., Schubauer-Berigan, M. K., & Kunzmann, A. T. (2025). Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. Lancet Oncology, S1470-2045(25)00403-6. Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., Samson, M., Sangari, L., Ungeheuer, M. N., Vacant, S., Zayoud, A., Donnadieu, F., Pelleau, S., Galmiche, S., Fontanet, A., & White, M. (2025). Correlates of protection against symptomatic COVID-19: The CORSER 5 case-control study. Open Forum Infectious Diseases, 12(1). Combes, J. D., Didelot, J. M., Radenne, S., Zaegel-Faucher, O., Lesage, A. C., Siproudhis, L., Piroth, L., Marchand, L., Heard, I., Hoyeau, N., Henno, S., Darragh, T. M., Alberts, C. J., Clifford, G. M., & Etienney, I.; ANRS-EP57-APACHES Study group. (2024). Cumulative detection of anal high-grade squamous intraepithelial lesions over 2-year follow-up in men who have sex with men living with human immunodeficiency virus in France. Journal of Infectious Diseases, 230(1). Martinez, F. J., Guillotte-Blisnick, M., Huon, C., England, P., Popovici, J., Laude, H., Arowas, L., Ungeheuer, M. N., Reimer, J. M., Carter, D., Reed, S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2023). Immunogenicity of a Plasmodium vivax vaccine based on the Duffy binding protein formulated using adjuvants compatible for use in humans. Scientific Reports, 13(1), 13904. Cuche, C., Mastrogiovanni, M., Juzans, M., Laude, H., Ungeheuer, M. N., Krentzel, D., Gariboldi, M. I., Scott-Algara, D., Madec, M., Goyard, S., Floch, C., Chauveau-Le Friec, G., Lafaye, P., Renaudat, C., Le Bidan, M., Micallef, C., Schmutz, S., Mella, S., Novault, S., Hasan, M., Duffy, D., Di Bartolo, V., & Alcover, A. (2023). T cell migration and effector function differences in familial adenomatous polyposis patients with APC gene mutations. Frontiers in Immunology, 14, 1163466.
Karagas, M. R., Kaldor, J., Michaelis, M., Muchengeti, M. M., Alfaiate, D., Argirion, I., Chen, X., Cunha, C., Hantz, S., Koljonen, V., Laude, H. C., Lui, W. O., Nevels, M. M., O’Brien, T. R., Scheurer, M. E., Touze, A., Wiemels, J. L., Benbrahim-Tallaa, L., de Conti, A., Facchin, C., Madia, F., Pasqual, E., Wedekind, R., Aguilera-Buenosvinos, I., Clifford, G., Deng, X., Dongoran, R. A., Ezzemni, S., Huang, Y., Suonio, E., Zhai, Y., Mattock, H., Schubauer-Berigan, M. K., & Kunzmann, A. T. (2025). Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. Lancet Oncology, S1470-2045(25)00403-6. Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., Samson, M., Sangari, L., Ungeheuer, M. N., Vacant, S., Zayoud, A., Donnadieu, F., Pelleau, S., Galmiche, S., Fontanet, A., & White, M. (2025). Correlates of protection against symptomatic COVID-19: The CORSER 5 case-control study. Open Forum Infectious Diseases, 12(1). Combes, J. D., Didelot, J. M., Radenne, S., Zaegel-Faucher, O., Lesage, A. C., Siproudhis, L., Piroth, L., Marchand, L., Heard, I., Hoyeau, N., Henno, S., Darragh, T. M., Alberts, C. J., Clifford, G. M., & Etienney, I.; ANRS-EP57-APACHES Study group. (2024). Cumulative detection of anal high-grade squamous intraepithelial lesions over 2-year follow-up in men who have sex with men living with human immunodeficiency virus in France. Journal of Infectious Diseases, 230(1). Martinez, F. J., Guillotte-Blisnick, M., Huon, C., England, P., Popovici, J., Laude, H., Arowas, L., Ungeheuer, M. N., Reimer, J. M., Carter, D., Reed, S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2023). Immunogenicity of a Plasmodium vivax vaccine based on the Duffy binding protein formulated using adjuvants compatible for use in humans. Scientific Reports, 13(1), 13904. Cuche, C., Mastrogiovanni, M., Juzans, M., Laude, H., Ungeheuer, M. N., Krentzel, D., Gariboldi, M. I., Scott-Algara, D., Madec, M., Goyard, S., Floch, C., Chauveau-Le Friec, G., Lafaye, P., Renaudat, C., Le Bidan, M., Micallef, C., Schmutz, S., Mella, S., Novault, S., Hasan, M., Duffy, D., Di Bartolo, V., & Alcover, A. (2023). T cell migration and effector function differences in familial adenomatous polyposis patients with APC gene mutations. Frontiers in Immunology, 14, 1163466.
Karagas, M. R., Kaldor, J., Michaelis, M., Muchengeti, M. M., Alfaiate, D., Argirion, I., Chen, X., Cunha, C., Hantz, S., Koljonen, V., Laude, H. C., Lui, W. O., Nevels, M. M., O’Brien, T. R., Scheurer, M. E., Touze, A., Wiemels, J. L., Benbrahim-Tallaa, L., de Conti, A., Facchin, C., Madia, F., Pasqual, E., Wedekind, R., Aguilera-Buenosvinos, I., Clifford, G., Deng, X., Dongoran, R. A., Ezzemni, S., Huang, Y., Suonio, E., Zhai, Y., Mattock, H., Schubauer-Berigan, M. K., & Kunzmann, A. T. (2025). Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. Lancet Oncology, S1470-2045(25)00403-6. Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., Samson, M., Sangari, L., Ungeheuer, M. N., Vacant, S., Zayoud, A., Donnadieu, F., Pelleau, S., Galmiche, S., Fontanet, A., & White, M. (2025). Correlates of protection against symptomatic COVID-19: The CORSER 5 case-control study. Open Forum Infectious Diseases, 12(1). Combes, J. D., Didelot, J. M., Radenne, S., Zaegel-Faucher, O., Lesage, A. C., Siproudhis, L., Piroth, L., Marchand, L., Heard, I., Hoyeau, N., Henno, S., Darragh, T. M., Alberts, C. J., Clifford, G. M., & Etienney, I.; ANRS-EP57-APACHES Study group. (2024). Cumulative detection of anal high-grade squamous intraepithelial lesions over 2-year follow-up in men who have sex with men living with human immunodeficiency virus in France. Journal of Infectious Diseases, 230(1). Martinez, F. J., Guillotte-Blisnick, M., Huon, C., England, P., Popovici, J., Laude, H., Arowas, L., Ungeheuer, M. N., Reimer, J. M., Carter, D., Reed, S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2023). Immunogenicity of a Plasmodium vivax vaccine based on the Duffy binding protein formulated using adjuvants compatible for use in humans. Scientific Reports, 13(1), 13904. Cuche, C., Mastrogiovanni, M., Juzans, M., Laude, H., Ungeheuer, M. N., Krentzel, D., Gariboldi, M. I., Scott-Algara, D., Madec, M., Goyard, S., Floch, C., Chauveau-Le Friec, G., Lafaye, P., Renaudat, C., Le Bidan, M., Micallef, C., Schmutz, S., Mella, S., Novault, S., Hasan, M., Duffy, D., Di Bartolo, V., & Alcover, A. (2023). T cell migration and effector function differences in familial adenomatous polyposis patients with APC gene mutations. Frontiers in Immunology, 14, 1163466.
Karagas, M. R., Kaldor, J., Michaelis, M., Muchengeti, M. M., Alfaiate, D., Argirion, I., Chen, X., Cunha, C., Hantz, S., Koljonen, V., Laude, H. C., Lui, W. O., Nevels, M. M., O’Brien, T. R., Scheurer, M. E., Touze, A., Wiemels, J. L., Benbrahim-Tallaa, L., de Conti, A., Facchin, C., Madia, F., Pasqual, E., Wedekind, R., Aguilera-Buenosvinos, I., Clifford, G., Deng, X., Dongoran, R. A., Ezzemni, S., Huang, Y., Suonio, E., Zhai, Y., Mattock, H., Schubauer-Berigan, M. K., & Kunzmann, A. T. (2025). Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus. Lancet Oncology, S1470-2045(25)00403-6. Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., Samson, M., Sangari, L., Ungeheuer, M. N., Vacant, S., Zayoud, A., Donnadieu, F., Pelleau, S., Galmiche, S., Fontanet, A., & White, M. (2025). Correlates of protection against symptomatic COVID-19: The CORSER 5 case-control study. Open Forum Infectious Diseases, 12(1). Combes, J. D., Didelot, J. M., Radenne, S., Zaegel-Faucher, O., Lesage, A. C., Siproudhis, L., Piroth, L., Marchand, L., Heard, I., Hoyeau, N., Henno, S., Darragh, T. M., Alberts, C. J., Clifford, G. M., & Etienney, I.; ANRS-EP57-APACHES Study group. (2024). Cumulative detection of anal high-grade squamous intraepithelial lesions over 2-year follow-up in men who have sex with men living with human immunodeficiency virus in France. Journal of Infectious Diseases, 230(1). Martinez, F. J., Guillotte-Blisnick, M., Huon, C., England, P., Popovici, J., Laude, H., Arowas, L., Ungeheuer, M. N., Reimer, J. M., Carter, D., Reed, S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2023). Immunogenicity of a Plasmodium vivax vaccine based on the Duffy binding protein formulated using adjuvants compatible for use in humans. Scientific Reports, 13(1), 13904. Cuche, C., Mastrogiovanni, M., Juzans, M., Laude, H., Ungeheuer, M. N., Krentzel, D., Gariboldi, M. I., Scott-Algara, D., Madec, M., Goyard, S., Floch, C., Chauveau-Le Friec, G., Lafaye, P., Renaudat, C., Le Bidan, M., Micallef, C., Schmutz, S., Mella, S., Novault, S., Hasan, M., Duffy, D., Di Bartolo, V., & Alcover, A. (2023). T cell migration and effector function differences in familial adenomatous polyposis patients with APC gene mutations. Frontiers in Immunology, 14, 1163466.